These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 24118504

  • 1. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
    Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T, Matsumoto K, Yonekura K, Yoshie O, Yano S.
    Cancer Sci; 2013 Dec; 104(12):1640-6. PubMed ID: 24118504
    [Abstract] [Full Text] [Related]

  • 2. Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer.
    Kasai S, Kuwayama N, Motoo Y, Kawashima A, Matsumoto K, Yano S, Matsushima K, Yasumoto K.
    Biochem Biophys Res Commun; 2022 Apr 16; 600():80-86. PubMed ID: 35196631
    [Abstract] [Full Text] [Related]

  • 3. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM.
    Clin Cancer Res; 2009 Jun 01; 15(11):3740-50. PubMed ID: 19470725
    [Abstract] [Full Text] [Related]

  • 4. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
    Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S.
    Clin Cancer Res; 2011 Jun 01; 17(11):3619-30. PubMed ID: 21482691
    [Abstract] [Full Text] [Related]

  • 5. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y, Zhang J, Tian Y, Xue C, Hu Z, Zhang L.
    Drug Des Devel Ther; 2015 Jun 01; 9():4897-907. PubMed ID: 26345996
    [Abstract] [Full Text] [Related]

  • 6. Influence of hepatocyte growth factor secreted from fibroblasts on the growth and invasion of scirrhous gastric cancer.
    Murakami N, Koufuji K, Shirouzu K.
    Int Surg; 2001 Jun 01; 86(3):151-7. PubMed ID: 11996071
    [Abstract] [Full Text] [Related]

  • 7. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Matsumoto K, Yonekura K, Yano S.
    J Thorac Oncol; 2014 Jun 01; 9(6):775-83. PubMed ID: 24828661
    [Abstract] [Full Text] [Related]

  • 8. Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer.
    Takiguchi S, Inoue K, Matsusue K, Furukawa M, Teramoto N, Iguchi H.
    Int J Oncol; 2017 Jul 01; 51(1):184-192. PubMed ID: 28498406
    [Abstract] [Full Text] [Related]

  • 9. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
    Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K, Mohri Y, Inoue Y, Goel A, Kusunoki M.
    Int J Cancer; 2012 Jun 15; 130(12):2912-21. PubMed ID: 21796631
    [Abstract] [Full Text] [Related]

  • 10. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma.
    Kawajiri H, Yashiro M, Shinto O, Nakamura K, Tendo M, Takemura S, Node M, Hamashima Y, Kajimoto T, Sawada T, Ohira M, Hirakawa K.
    Clin Cancer Res; 2008 May 01; 14(9):2850-60. PubMed ID: 18451253
    [Abstract] [Full Text] [Related]

  • 11. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
    Kwon Y, Smith BD, Zhou Y, Kaufman MD, Godwin AK.
    Oncogene; 2015 Jan 08; 34(2):144-53. PubMed ID: 24362531
    [Abstract] [Full Text] [Related]

  • 12. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.
    Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O, Saiki I.
    Cancer Res; 2006 Feb 15; 66(4):2181-7. PubMed ID: 16489019
    [Abstract] [Full Text] [Related]

  • 13. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S.
    Clin Cancer Res; 2012 Jul 01; 18(13):3592-602. PubMed ID: 22553343
    [Abstract] [Full Text] [Related]

  • 14. Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-β signaling.
    Hasegawa T, Yashiro M, Nishii T, Matsuoka J, Fuyuhiro Y, Morisaki T, Fukuoka T, Shimizu K, Shimizu T, Miwa A, Hirakawa K.
    Int J Cancer; 2014 Apr 15; 134(8):1785-95. PubMed ID: 24155219
    [Abstract] [Full Text] [Related]

  • 15. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
    Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K.
    Gastroenterology; 2006 Nov 15; 131(5):1530-41. PubMed ID: 17101326
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.